Christos E Kyriakopoulos1, Elisabeth I Heath2, Jens C Eickhoff3, Jill Kolesar3, Mulusew Yayehyirad3, Thomas Moll4, George Wilding3, Glenn Liu3. 1. University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, 53792, USA. ckyriako@medicine.wisc.edu. 2. Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI, 48201, USA. 3. University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, 53792, USA. 4. Adamis Pharmaceuticals Corporation, 11682 El Camino Real, Suite 300, San Diego, CA, 92130, USA.
Abstract
BACKGROUND: A phase 1/2a dose escalation study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) was conducted to determine maximum tolerated dose (MTD), recommended phase 2 dose, toxicities and efficacy in men with castrate-resistant prostate cancer (CRPC). METHODS: This open label phase 1/2a study utilizes a time-to-event reassessment method (TITE-CRM) design. Patients in cohorts of 3 were treated with escalating doses of APC-100 (900 mg-2400 mg) orally once daily continuously. Cycles were 28 days. RESULTS: Twenty patients with CRPC were enrolled in the dose escalation cohort. One possible DLT (elevated ALT) was seen at dose level 1. No other DLTs were seen and no dose reductions were required. Most frequent AEs included nausea (grade 1 in 6 patients) and elevated transaminases (grade 1-3 in 5 patients). After enrolment of 20 patients the MTD was not reached, however the maximal feasible dose was exceeded due to the number of capsules ingested. Five of the 20 patients had stable disease as their best response. The median progression free survival (PFS) for the cohort was 2.8 months (range 1-8). CONCLUSIONS: APC-100 is a novel agent with dual mechanism of action functioning both as potent antioxidant as well as antiandrogen. No detectable APC-100 was found in the plasma at dose level 5 (2100 mg) and it was felt that maximal feasibility was nearly reached. APC-100 is being reformulated as a tablet to allow further dose escalation. Once a recommended phase 2 dose is established, future studies in prostate cancer chemoprevention should be conducted.
BACKGROUND: A phase 1/2a dose escalation study of APC-100 (2,2,5,7,8-Pentamethyl-6-chromanol) was conducted to determine maximum tolerated dose (MTD), recommended phase 2 dose, toxicities and efficacy in men with castrate-resistant prostate cancer (CRPC). METHODS: This open label phase 1/2a study utilizes a time-to-event reassessment method (TITE-CRM) design. Patients in cohorts of 3 were treated with escalating doses of APC-100 (900 mg-2400 mg) orally once daily continuously. Cycles were 28 days. RESULTS: Twenty patients with CRPC were enrolled in the dose escalation cohort. One possible DLT (elevated ALT) was seen at dose level 1. No other DLTs were seen and no dose reductions were required. Most frequent AEs included nausea (grade 1 in 6 patients) and elevated transaminases (grade 1-3 in 5 patients). After enrolment of 20 patients the MTD was not reached, however the maximal feasible dose was exceeded due to the number of capsules ingested. Five of the 20 patients had stable disease as their best response. The median progression free survival (PFS) for the cohort was 2.8 months (range 1-8). CONCLUSIONS: APC-100 is a novel agent with dual mechanism of action functioning both as potent antioxidant as well as antiandrogen. No detectable APC-100 was found in the plasma at dose level 5 (2100 mg) and it was felt that maximal feasibility was nearly reached. APC-100 is being reformulated as a tablet to allow further dose escalation. Once a recommended phase 2 dose is established, future studies in prostate cancer chemoprevention should be conducted.
Entities:
Keywords:
APC-100; Oxidative stress; Phase I; Prostate cancer
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: Hirak S Basu; Todd A Thompson; Dawn R Church; Cynthia C Clower; Farideh Mehraein-Ghomi; Corey A Amlong; Christopher T Martin; Patrick M Woster; Mary J Lindstrom; George Wilding Journal: Cancer Res Date: 2009-09-22 Impact factor: 12.701
Authors: Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh Journal: JAMA Date: 2008-06-18 Impact factor: 56.272
Authors: Nolan A Wages; Thomas M Braun; Daniel P Normolle; Matthew J Schipper Journal: Int J Radiat Oncol Biol Phys Date: 2022-07-01 Impact factor: 8.013
Authors: Gagan Chhabra; Chandra K Singh; Mary Ann Ndiaye; Samantha Fedorowicz; Arielle Molot; Nihal Ahmad Journal: Cancer Lett Date: 2018-02-20 Impact factor: 8.679
Authors: Erik van Werkhoven; Samantha Hinsley; Eleni Frangou; Jane Holmes; Rosemarie de Haan; Maria Hawkins; Sarah Brown; Sharon B Love Journal: BMC Med Res Methodol Date: 2020-06-22 Impact factor: 4.615
Authors: Giorgio Aquila; Andrea David Re Cecconi; Jeffrey J Brault; Oscar Corli; Rosanna Piccirillo Journal: Cells Date: 2020-11-24 Impact factor: 6.600